The investigators assembled in the DF/HCC Prostate Cancer SPORE have a substantial record in mentorship and development of junior faculty working in the prostate cancer field (detailed below). The goal of the Career Development Award Program of our SPORE is to build upon this record and continue a formal process for the identification, selection, funding, and mentoring of individuals pursuing careers in the study of the basic, translational, and clinical aspects of prostate cancer. We will set aside $100,000 per year for the Career Development Awards. This will be supplemented with an additional $175,000 in the form of institutional support from the DFCI Prostate Cancer Fund, MGH, and the Prostate Cancer Walk. Up to two individuals will be awarded each year as much as two years of funding at $50,000 per year. The award will facilitate the research and development of independence of basic, translational, and clinical investigators within the DF/HCC Prostate Cancer Program. Thus, candidates will be fellows, postdoctoral fellows, and junior faculty within the various training programs across the Harvard campus. It is our goal to attract, mentor and assure the success of several CDA recipients. Success herein is defined as the development of physician/scientists in training to independent investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090381-09
Application #
8094497
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
9
Fiscal Year
2010
Total Cost
$183,011
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Graff, Rebecca E; Ahearn, Thomas U; Pettersson, Andreas et al. (2018) Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:193-200
Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :
Dickerman, Barbra A; Torfadottir, Johanna E; Valdimarsdottir, Unnur A et al. (2018) Midlife metabolic factors and prostate cancer risk in later life. Int J Cancer 142:1166-1173
McKay, Rana R; Werner, Lillian; Jacobus, Susanna J et al. (2018) A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer :
Larimer, Benjamin M; Bloch, Emily G; Nesti, Sarah et al. (2018) The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. Clin Cancer Res :
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917
Chen, Sen; Cai, Changmeng; Sowalsky, Adam G et al. (2018) BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Res 78:5203-5215
Pakula, Hubert; Linn, Douglas E; Schmidt, Daniel R et al. (2018) Protocols for Studies on TMPRSS2/ERG in Prostate Cancer. Methods Mol Biol 1786:131-151
Elfandy, Habiba; Armenia, Joshua; Pederzoli, Filippo et al. (2018) Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res :
Han, W; Gao, S; Barrett, D et al. (2018) Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Oncogene 37:710-721

Showing the most recent 10 out of 261 publications